arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

DiaMedica Therapeutics Inc.

DMAC
$9.04 ▼ -1.75 (-16.22%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
36 Visible periods
23 Metrics
Peer-ranked Benchmarks
Price Chart
28
Health
Poor
Bearish
auto_awesome

Analytical Summary

DiaMedica Therapeutics Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $487.2M
Dividend Yield —
Revenue Growth —
Op. Margin None
ROIC -27.4% ↘
FCF / Share $-0.15 ↗
Trailing P/E —
Price / Book 12.7x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

36-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Net Income Profit after all expenses
$-10.04M
↓ -30.3% —
FCF / Share Free cash flow per share
$-0.15
↑ +10.9% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↓
15
Cash Quality →
60

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 10 years · 36 quarters